#United States #NRx Pharmaceuticals #Palm Beach #Hope Therapeutics #Mar-A-Lago

Recent Investor Workshop at Mar-A-Lago Club

On January 10, 2025, HOPE Therapeutics™, Inc. (HOPE), a healthcare delivery firm focused on mental health, along with its parent company, NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), conducted a significant investor workshop at the prestigious Mar-A-Lago Club in Palm Beach, FL. The event attracted qualified institutional buyers, with prominent figures such as Jonathan Javitt, MD, MPH, Chairman and CEO of NRx, also present.

The gathering was centered around the ambitious plans of HOPE to expand its network of interventional psychiatry practices aimed at addressing critical mental health issues, particularly suicidal depression and PTSD. Key discussions highlighted HOPE's mission of establishing a best-in-class international network of profitable clinics that utilize innovative therapeutic approaches.

Financial Commitments

A considerable highlight of the workshop was the commitment from Smith and Sauer, a private investment firm, which pledged $25 million in financing. This funding is expected to leverage bank financing to potentially secure a revenue stream of $100 million on a pro-forma basis from the clinics established under the HOPE brand. The investors discussed the progress made on recent clinic acquisitions, which indicate a strong trajectory for growth.

Future Expansion Plans

The workshop attendees also explored various mechanisms for follow-on non-dilutive financing, allowing HOPE to expand its network further. The proposed plans aim at establishing an additional 50 clinics in 2026 and an impressive 100 clinics by 2027. Such expansion reflects HOPE's commitment to increasing access to vital mental health services.

Technological Integration

In addition to clinic expansion, discussions also focused on technology integration within the network. There are ambitious plans to establish a CRM-based IT and telepsychiatry framework that would seamlessly connect all clinics, enhancing patient care and operational efficiency.

Positive Response and Next Steps

The enthusiastic response from the attendees was noted by Jonathan Javitt, MD MPH, who expressed satisfaction over the insightful questions and interest shown. He emphasized HOPE’s mission in combatting suicidality, particularly among military and veteran communities, resonated deeply with the sophisticated audience present that evening.

Following the successful event, a second meeting is scheduled for the last week of January 2025, set to include not just qualified institutional buyers but also accredited investors, which reflects the growing interest in HOPE’s mission and strategy.

About HOPE Therapeutics and NRx Pharmaceuticals

HOPE Therapeutics is a healthcare delivery platform focused on establishing interventional psychiatry clinics that provide critical treatments, including ketamine therapy and TMS (Transcranial Magnetic Stimulation), designed to help individuals suffering from debilitating conditions related to mental health. Meanwhile, NRx Pharmaceuticals is dedicated to advancing clinical-stage biopharmaceutical products that address suicidal depression and PTSD, employing an NMDA platform to develop impactful therapeutics. Currently, NRx is working to expedite the approval of its investigational therapies through the FDA.

In conclusion, the recent discussions at Mar-A-Lago not only indicate strong financial backing for HOPE Therapeutics but also highlight an innovative approach toward mental health care that is set to scale significantly in the coming years.